文献速递传染病防控与疫情报告免疫规划

火鸡采用初免-加强免疫后对分支2.3.4.4 H5N2高致病性禽流感病毒的短期和长期保护效力

Short- and long-term protective efficacy against clade 2.3.4.4 H5N2 highly pathogenic avian influenza virus following prime-boost vaccination in turkeys.
PubMed 文献 · Vaccine · 2017-09-06

本研究在火鸡中采用两种疫苗(甲病毒复制子疫苗与佐剂灭活反向遗传疫苗)的三种初免-加强方案,于6周龄和16周龄以原型新型分支2.3.4.4 H5N2高致病性禽流感病毒攻击评估效力。三种方案在6周龄攻击后均具保护性,显著减少排毒与死亡;16周龄攻击后保护效果差异显著,以甲病毒复制子初免后佐剂灭活疫苗加强保护最佳,甲病毒复制子疫苗两次接种保护最差。

要点

  • 三种初免-加强方案在6周龄攻击后均显著减少排毒与死亡。
  • 16周龄攻击后保护效果差异显著,甲病毒复制子初免加佐剂灭活疫苗加强保护最佳。
  • 甲病毒复制子疫苗两次接种在16周龄攻击后保护最差。

核心结论

  • 三种初免-加强方案在6周龄火鸡攻击后均具保护性,显著减少排毒与死亡;16周龄攻击后保护效果差异显著,甲病毒复制子初免加佐剂灭活疫苗加强保护最佳,甲病毒复制子疫苗两次接种保护最差。
  • 研究强调不仅需研究不同疫苗平台,还需研究免疫策略以最大化对高致病性禽流感病毒的保护,尤其关乎疫苗诱导免疫应答的持久性。

研究设计与样本

  • 在火鸡中开展疫苗接种研究,采用3种初免-加强方案,组合使用甲病毒复制子疫苗与佐剂灭活反向遗传疫苗两种疫苗。
  • 于6周龄和16周龄以原型新型分支2.3.4.4 H5N2高致病性禽流感病毒攻击评估疫苗效力。

主要发现

  • 三种疫苗方案在6周龄攻击后均具保护性,显著减少病毒排毒与死亡。
  • 16周龄火鸡攻击后见显著差异:甲病毒复制子初免后佐剂灭活疫苗加强保护最佳,甲病毒复制子疫苗两次接种保护最差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Highly pathogenic avian influenza virus (HPAIV) infections are frequently associated with systemic disease and high mortality in domestic poultry, particularly in chickens and turkeys. Clade 2.3.4.4 represents a genetic cluster within the Asian HPAIV H5 Goose/Guangdong lineage that has transmitted through migratory birds and spread throughout the world. In 2014, clade 2.3.4.4 strains entered the U.S. via the Pacific flyway, reassorted with local strains of the North American lineage, and produced novel HPAIV strains of the H5N1, H5N2, and H5N8 subtypes. By 2015, the H5N2 HPAIVs disseminated eastwards within the continental U.S. and Canada and infected commercial poultry, causing the largest animal health outbreak in recent history in the U.S. The outbreak was controlled by traditional mass depopulation methods, but the outbreak was of such magnitude that it led to the consideration of alternative control measures, including vaccination. In this regard, little information is available on the long-term protection of turkeys vaccinated against avian influenza. In this report, a vaccination study was carried out in turkeys using 3 prime-boost approaches with a combination of 2 different vaccines, an alphavirus-based replicon vaccine and an adjuvanted-inactivated reverse genetics vaccine. Vaccine efficacy was assessed at 6 and 16weeks of age following challenge with a prototypic novel clade 2.3.4.4 H5N2 HPAIV. All three vaccines protocols were protective with significantly reduced virus shedding and mortality after challenge at 6weeks of age. In contrast, significant variations were seen in 16-week old turkeys after challenge: priming with the alphavirus-based replicon followed by boost with the adjuvanted-inactivated vaccine conferred the best protection, whereas the alphavirus-based replicon vaccine given twice provided the least protection. Our study highlights the importance of studying not only different vaccine platforms but also vaccination strategies to maximize protection against HPAIV especially with regards to the longevity of vaccine-induced immune response.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Santos JJS, Obadan AO, Garcia SC, et al. Short- and long-term protective efficacy against clade 2.3.4.4 H5N2 highly pathogenic avian influenza virus following prime-boost vaccination in turkeys. Vaccine. 2017. PMID: 28886943. doi:10.1016/j.vaccine.2017.08.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。